Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"MycoMedica Life Sciences","sponsor":"Obvious Ventures","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"MycoMedica Life Sciences, PBC Secures $60 Million in Funding To Fuel Fungi-Based Drug Development for Prevention and Treatment of Psychiatric and Neurological Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by MycoMedica Life Sciences

    Menu

    MycoMedica Life Sciences

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              MycoMedica Life Sciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MycoMedica Life Sciences, PBC Secures $60 Million in Funding To Fuel Fungi-Based Drug Development for Prevention and Treatment of Psychiatric and Neurological Disorders

              Details:

              The proceeds from the financing will be used to advance the company’s next stage of operations having psilocybine on the path to FDA approval for an Investigational New Drug Application (IND) – pre-clinical research and initial clinical trials of the Stamets Stack.

              Lead Product(s): Psilocybine

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: Obvious Ventures

              Deal Size: $60.0 million Upfront Cash: Undisclosed

              Deal Type: Financing June 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY